BioSpace News Archive

Soundbite Medical Solutions Inc. (SBMS), a medical device company leveraging its proprietary shock wave technology for the interventional treatment of calcific occlusive peripheral and coronary arterial diseases, today announced that members of its senior management team will participate in the 32nd Annual Oppenheimer Healthcare Conference.

Mountain Valley MD Holdings Inc. is pleased to announce the appointment of Dr. Elizabeth Norton to an advisory position to support MVMD’s key Quicksome™ vaccine and cold chain projects.

Mason, innovator of the only fully managed infrastructure for developing and delivering dedicated smart devices, today announced results from a recent research study about the current processes, challenges and opportunities for bringing an IoT product for remote patient management (RPM) and electronic clinical outcome assessments (eCOA) to market.

Hemogenyx Pharmaceuticals plc, the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that it has achieved proof of concept for its Chimeric Bait Receptor platform technology.

Bruker Corporation announced that its Board of Directors has appointed Philip Ma, Ph.D. to serve on its board, effective as of April 1, 2022.

The Ivy Brain Tumor Center at Barrow Neurological Institute, the largest early-phase drug development program for brain cancer, announced the opening of a new Phase 0/1b clinical trial to evaluate AZD1390, an Ataxia telangiectasia mutant (ATM) kinase inhibitor being developed by AstraZeneca, in patients with recurrent grade IV gliomas.

Monteris Medical announced today that a study on patient preferences for treating drug-resistant epilepsy (DRE) has been published in the peer-reviewed journal, Epilepsy and Behavior.

The contract research organization (CROs) services market is expected to reach valuation US$ 111.26 billion by 2028, growing at a CAGR of 10.1% from 2021 to 2030.

Biogen Inc. (Nasdaq: BIIB) announced that The Journal of Prevention of Alzheimer’s Disease (JPAD) today published a peer-reviewed manuscript detailing data from the pivotal Phase 3 EMERGE and ENGAGE trials for ADUHELM® (aducanumab-avwa) 100 mg/mL injection for intravenous use in early Alzheimer’s disease.

Growing demand for brain monitoring devices for monitoring and analyzing functions of brain, and increasing number of people suffering from neurological disorders are key factors driving market revenue growth.